ITGB4 and neoplasm: Their in vitro and in vivo study demonstrated a synergistic anti-tumor efficacy from the combination of carfilzomib and sotorasib in NSCLC cell lines and xenografts through downregulating ITGB4 and β-catenin expression (92).